Kyverna Therapeutics, Inc. (KYTX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kyverna Therapeutics, Inc. (KYTX) trades at $8.13 with AI Score 41/100 (Grade C). Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Market cap: $494M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026KYTX stock analysis for 2026: Analysts have set a consensus price target of $33.00 for Kyverna Therapeutics, Inc., suggesting 305.9% upside from the current price of $8.13. The AI MoonshotScore is 41/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
KYTX: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Kyverna Therapeutics, Inc. (KYTX) Healthcare & Pipeline Overview
Kyverna Therapeutics, Inc. pioneers cell therapies for autoimmune diseases, focusing on its lead candidate, KYV-101, an autologous CD19 CAR T-cell therapy. Currently in Phase I and II clinical trials targeting lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, Kyverna aims to transform treatment paradigms in the biotechnology sector.
What Is the Investment Thesis for KYTX?
Kyverna Therapeutics, Inc. presents a notable research candidate within the biotechnology sector, driven by its innovative CAR T-cell therapies targeting autoimmune diseases. The primary value driver is the clinical progress of KYV-101, currently in Phase I and Phase II trials, with potential for accelerated approval pathways if clinical data are promising. Successful trials and subsequent commercialization of KYV-101 could generate substantial revenue, addressing a significant unmet need in lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Growth catalysts include positive clinical trial readouts expected over the next 12-24 months and the advancement of KYV-201 into clinical trials. Key risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's market capitalization of $494M reflects its early-stage nature, offering potential upside with successful clinical and regulatory milestones.
Based on FMP financials and quantitative analysis
KYTX Key Highlights
KYV-101, the lead product candidate, is in Phase I clinical trial for lupus nephritis and systemic sclerosis.
- KYV-101 is also in Phase II clinical trial for myasthenia gravis and multiple sclerosis.
- KYV-201, an allogeneic CD19 CAR T-cell product candidate, is in preclinical stage to treat multiple autoimmune diseases.
- Kyverna has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
- The company also collaborates with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.
Who Are KYTX's Competitors?
KYTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
| CRMD CorMedix Inc. | $8.33 | -2.19% | $654M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.89 | -1.98% | $703M | 93 |
| GNFTF Genfit S.A. | $16.28 | -1.33% | $816M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KYTX's Key Strengths?
Innovative CAR T-cell therapy platform targeting autoimmune diseases.
- Lead product candidate, KYV-101, in Phase I and Phase II clinical trials.
- Strategic collaborations with Intellia Therapeutics and Kite.
- Experienced management team with expertise in cell therapy development.
What Are KYTX's Weaknesses?
Clinical-stage company with no approved products and no revenue.
- High cash burn rate associated with clinical trials and research and development.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited manufacturing capacity for CAR T-cell therapies.
What Could Drive KYTX Stock Higher?
KYTX catalyst: Interim data readout from the Phase I clinical trial of KYV-101 in lupus nephritis (Q4 2026).
- Initiation of Phase I clinical trial for KYV-201, the allogeneic CD19 CAR T-cell product candidate (Q1 2027).
- Enrollment and data collection from the Phase II clinical trial of KYV-101 in myasthenia gravis and multiple sclerosis.
- Progress in strategic collaborations with Intellia Therapeutics and Kite.
What Are the Key Risks for KYTX?
Financial-distress signal — its Altman Z-Score of 1.22 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-81.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for KYV-101 or KYV-201.
- Regulatory hurdles and rejection of product candidates by the FDA or other regulatory agencies.
- Competition from established pharmaceutical companies and other CAR T-cell developers.
- Adverse events or safety concerns associated with CAR T-cell therapies.
- High cash burn rate and need for additional funding to support clinical trials and research and development.
What Are the Growth Opportunities for KYTX?
- Expansion into New Autoimmune Indications: Kyverna has the opportunity to expand its pipeline beyond its current targets of lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Exploring CAR T-cell therapies for other autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, and autoimmune hepatitis, could significantly broaden its market reach. The market for rheumatoid arthritis therapies alone is projected to reach $30 billion by 2027, offering a substantial growth avenue.
- Advancement of KYV-201 into Clinical Trials: The successful transition of KYV-201, its allogeneic CD19 CAR T-cell product candidate, into clinical trials represents a significant growth opportunity. Allogeneic therapies offer advantages over autologous therapies in terms of scalability and cost, potentially making them more accessible to a wider patient population. Positive clinical data for KYV-201 could attract further investment and partnerships.
- Strategic Collaborations and Licensing Agreements: Kyverna can leverage strategic collaborations and licensing agreements to accelerate its research and development efforts. Partnering with larger pharmaceutical companies or specialized technology providers can provide access to resources, expertise, and funding. The existing collaborations with Intellia Therapeutics and Kite demonstrate the company's ability to forge such partnerships.
- Geographic Expansion: While currently focused on the US market, Kyverna has the opportunity to expand its operations into other regions, such as Europe and Asia. These markets have a significant patient population with autoimmune diseases and a growing demand for innovative therapies. Regulatory approvals and market access strategies will be crucial for successful geographic expansion.
- Development of Next-Generation CAR T-Cell Technologies: Investing in the development of next-generation CAR T-cell technologies, such as improved CAR designs, enhanced targeting strategies, and reduced toxicity profiles, can provide a competitive edge. These advancements can lead to more effective and safer therapies, attracting both patients and investors.
What Are KYTX's Competitive Advantages?
- Proprietary CAR T-cell technology platform.
- Clinical data demonstrating efficacy in autoimmune disease treatment.
- Strategic collaborations with leading biotechnology companies.
- Strong intellectual property portfolio protecting its CAR T-cell therapies.
What Does KYTX Do?
Kyverna Therapeutics, Inc., established in 2018 and headquartered in Emeryville, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for patients with autoimmune diseases. Originally named BAIT Therapeutics, Inc., the company rebranded in October 2019 to Kyverna Therapeutics, Inc., signaling a refined focus on its core mission. The company's lead product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently undergoing Phase I clinical trials for lupus nephritis and systemic sclerosis, and Phase II clinical trials for myasthenia gravis and multiple sclerosis. KYV-101 represents a significant advancement in the treatment of these debilitating conditions. In addition to KYV-101, Kyverna is developing KYV-201, an allogeneic CD19 CAR T-cell product candidate in the preclinical stage, designed to treat a broader range of autoimmune diseases. The company is also exploring therapies for other autoimmune conditions, including inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis. Kyverna has established strategic collaborations, including a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product, and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. These partnerships underscore Kyverna's commitment to innovation and expanding its therapeutic pipeline.
What Products and Services Does KYTX Offer?
- Develop autologous CD19 CAR T-cell therapies for autoimmune diseases.
- Focus on treating lupus nephritis and systemic sclerosis with KYV-101.
- Develop allogeneic CD19 CAR T-cell therapies for autoimmune diseases.
- Target myasthenia gravis and multiple sclerosis with KYV-101.
- Research therapies for inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
- Collaborate with Intellia Therapeutics on allogeneic CD19-directed CAR cell therapy.
- Partner with Kite to develop programs for autoimmune and inflammatory diseases.
How Does KYTX Make Money?
- Develop and commercialize CAR T-cell therapies for autoimmune diseases.
- Generate revenue through product sales upon regulatory approval.
- Establish strategic collaborations and licensing agreements to fund research and development.
- Potentially receive milestone payments and royalties from partnerships.
What Industry Does KYTX Operate In?
Kyverna Therapeutics operates within the rapidly evolving biotechnology industry, specifically targeting the autoimmune disease market. This market is characterized by a high unmet need for effective and durable therapies. The CAR T-cell therapy space is competitive, with companies like Novartis and Gilead already having approved CAR T-cell therapies for cancer. However, Kyverna is focusing on autoimmune diseases, a relatively untapped area for CAR T-cell therapy. The global autoimmune disease market is projected to reach $150 billion by 2028, driven by increasing prevalence and advancements in diagnostic and therapeutic options. Kyverna's success hinges on its ability to navigate the complex regulatory landscape and demonstrate clinical efficacy in its target indications.
Who Are KYTX's Key Customers?
- Patients suffering from autoimmune diseases such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.
- Hospitals and clinics that administer CAR T-cell therapies.
- Healthcare providers specializing in autoimmune disease treatment.
- Pharmaceutical companies through licensing and collaboration agreements.
Company Profile
Kyverna Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Emeryville, US. The company is led by CEO Warner Biddle. KYTX has traded publicly since 2024.
How Kyverna Therapeutics, Inc. Is Valued
Kyverna Therapeutics, Inc. carries a market capitalization of $494M, placing it in the small-cap category. Relative to its peer group, KYTX's quantitative score of 41/100 is below the peer average of 74/100.
Key Financial Metrics
Return on equity for Kyverna Therapeutics, Inc. stands at -81.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -39.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Kyverna Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.22 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Kyverna Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 6.2% above estimates on average.
Forward Outlook
Wall Street analysts project Kyverna Therapeutics, Inc. revenue of about $12.5M for fiscal 2026, with EPS near $-2.87. The estimate reflects 4 contributing analysts.
KYTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Kyverna's recent insider buying suggests strong confidence from those closest to the company, often a positive signal for future performance.
- The overall community sentiment appears optimistic, with many traders discussing potential long-term growth based on their pipeline.
- Kyverna's focus on novel autoimmune therapies positions it well in a market with high unmet needs and significant growth potential.
- Recent market developments, particularly positive clinical trial updates in similar therapeutic areas, are creating a halo effect for Kyverna.
Bear Case
- Some community members are expressing concerns about the company's cash burn rate and potential need for future capital raises.
- Despite positive sentiment, there are lingering questions about the scalability of Kyverna's manufacturing process for its cell therapies.
- Increased competition in the autoimmune space from larger, established players could put pressure on Kyverna's market share.
- Recent insider sales, while not as prominent as buys, are causing some to question the long-term commitment of certain key individuals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KYTX Latest News
No recent news available for KYTX.
KYTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KYTX.
Price Targets
Consensus target: $33.00
KYTX MoonshotScore
What does this score mean?
The MoonshotScore rates KYTX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Warner Biddle
CEO
Warner Biddle is the Chief Executive Officer of Kyverna Therapeutics, Inc. He brings extensive experience in the biopharmaceutical industry, with a focus on strategic leadership and corporate development. Prior to joining Kyverna, he held leadership positions at various biotechnology companies, where he oversaw the development and commercialization of innovative therapies. His background includes a strong understanding of clinical development, regulatory affairs, and market access strategies. He is responsible for managing 112 employees.
Track Record: Under Warner Biddle's leadership, Kyverna Therapeutics has advanced its lead product candidate, KYV-101, into Phase I and Phase II clinical trials. He has also secured strategic collaborations with Intellia Therapeutics and Kite, expanding the company's research and development capabilities. His focus on building a strong team and fostering a culture of innovation has contributed to Kyverna's progress in the competitive CAR T-cell therapy space.
Common Questions About KYTX (Healthcare)
What does the AI Score mean for KYTX?
KYTX holds an AI Score of 41/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Their lead product candidate, KYV-101, is currently in Phase I …
What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Their lead product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently in Phase I and Phase II clinical trials for lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.
What do analysts say about KYTX stock?
As a clinical-stage biopharmaceutical company, analyst coverage on KYTX stock is likely focused on the clinical progress of KYV-101 and KYV-201. Key valuation metrics would include potential peak sales for its lead product candidates, probability of success in clinical trials, and the company's cash runway.
What are the main risks for KYTX?
The main risks for Kyverna Therapeutics, Inc. include clinical trial failures or delays, regulatory hurdles, competition from established pharmaceutical companies, and adverse events associated with CAR T-cell therapies. As a clinical-stage company, Kyverna is heavily reliant on the successful development and approval of its product candidates. Any setbacks in clinical trials or regulatory reviews could significantly impact the company's value.
How does Kyverna Therapeutics, Inc. navigate regulatory approval processes?
Kyverna Therapeutics, Inc. navigates regulatory approval processes by adhering to rigorous clinical trial protocols, maintaining open communication with regulatory agencies like the FDA, and compiling comprehensive data packages to support its product candidates. The company focuses on demonstrating the safety and efficacy of its CAR T-cell therapies through well-designed clinical trials.
What are the key growth opportunities for KYTX in healthcare?
Kyverna Therapeutics, Inc.'s key growth opportunities lie in expanding its pipeline of CAR T-cell therapies to address a broader range of autoimmune diseases, advancing KYV-201 into clinical trials, and securing additional partnerships and funding. The company can also explore geographic expansion into Europe and Asia, where there is a significant unmet need for effective autoimmune disease treatments.
What are the key factors to evaluate for KYTX?
Kyverna Therapeutics, Inc. (KYTX) holds an AI score of 41/100 (low). Analysts target $33.00 (+306%). presents a notable research candidate within the biotechnology sector, driven by its innovative CAR T-cell therapies targeting autoimmune diseases. Not financial advice.
How frequently does KYTX data refresh on this page?
KYTX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KYTX's recent stock price performance?
Kyverna Therapeutics, Inc. (KYTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative CAR T-cell therapy platform targeting autoimmune diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is for informational purposes only and does not constitute investment advice.